<!DOCTYPE html >
<html lang="en">
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p150" style="overflow: hidden; position: relative; background-color: white; width: 433px; height: 649px;">

<!-- Begin shared CSS values -->
<style class="shared-css" type="text/css" >
.t {
	-webkit-transform-origin: top left;
	-moz-transform-origin: top left;
	-o-transform-origin: top left;
	-ms-transform-origin: top left;
	-webkit-transform: scale(0.25);
	-moz-transform: scale(0.25);
	-o-transform: scale(0.25);
	-ms-transform: scale(0.25);
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
}
</style>
<!-- End shared CSS values -->


<!-- Begin inline CSS -->
<style type="text/css" >

#t1_150{left:4px;top:233px;letter-spacing:-0.1px;}
#t2_150{left:4px;top:78px;letter-spacing:-0.3px;}
#t3_150{left:4px;top:629px;}
#t4_150{left:59px;top:40px;letter-spacing:-1px;word-spacing:8.7px;}
#t5_150{left:59px;top:56px;letter-spacing:-1px;}
#t6_150{left:52px;top:73px;}
#t7_150{left:59px;top:73px;letter-spacing:-1px;}
#t8_150{left:86px;top:73px;letter-spacing:-0.9px;word-spacing:9.6px;}
#t9_150{left:59px;top:88px;letter-spacing:-1px;word-spacing:0.3px;}
#ta_150{left:59px;top:104px;letter-spacing:-1px;word-spacing:1.3px;}
#tb_150{left:59px;top:119px;letter-spacing:-1px;word-spacing:5.1px;}
#tc_150{left:59px;top:134px;letter-spacing:-0.9px;word-spacing:-0.5px;}
#td_150{left:52px;top:152px;letter-spacing:-1px;word-spacing:2.6px;}
#te_150{left:177px;top:152px;letter-spacing:-1.2px;word-spacing:2.8px;}
#tf_150{left:257px;top:152px;letter-spacing:-1px;word-spacing:2.6px;}
#tg_150{left:52px;top:167px;letter-spacing:-1px;}
#th_150{left:52px;top:184px;letter-spacing:-1px;word-spacing:-0.1px;}
#ti_150{left:43px;top:215px;letter-spacing:-0.9px;word-spacing:-0.5px;}
#tj_150{left:61px;top:232px;letter-spacing:-0.9px;word-spacing:-0.1px;}
#tk_150{left:61px;top:249px;letter-spacing:-1px;}
#tl_150{left:67px;top:249px;letter-spacing:-1px;word-spacing:2.8px;}
#tm_150{left:135px;top:249px;}
#tn_150{left:142px;top:249px;letter-spacing:-0.9px;word-spacing:2.9px;}
#to_150{left:67px;top:265px;letter-spacing:-1px;word-spacing:-0.1px;}
#tp_150{left:61px;top:282px;letter-spacing:-1px;}
#tq_150{left:67px;top:282px;letter-spacing:-1px;word-spacing:3.2px;}
#tr_150{left:67px;top:297px;letter-spacing:-1px;word-spacing:-0.1px;}
#ts_150{left:52px;top:315px;letter-spacing:-1px;word-spacing:-0.1px;}
#tt_150{left:61px;top:332px;letter-spacing:-1px;}
#tu_150{left:67px;top:332px;letter-spacing:-1px;word-spacing:-0.9px;}
#tv_150{left:67px;top:348px;letter-spacing:-1px;word-spacing:-0.1px;}
#tw_150{left:52px;top:365px;letter-spacing:-0.9px;}
#tx_150{left:61px;top:382px;letter-spacing:-0.9px;word-spacing:-0.2px;}
#ty_150{left:61px;top:400px;letter-spacing:-0.9px;word-spacing:-0.2px;}
#tz_150{left:201px;top:400px;letter-spacing:-0.9px;word-spacing:-0.3px;}
#t10_150{left:61px;top:417px;letter-spacing:-1px;word-spacing:-0.1px;}
#t11_150{left:61px;top:435px;letter-spacing:-1px;word-spacing:-0.1px;}
#t12_150{left:61px;top:452px;letter-spacing:-0.9px;word-spacing:-0.2px;}
#t13_150{left:61px;top:470px;letter-spacing:-1px;word-spacing:-0.2px;}
#t14_150{left:43px;top:505px;letter-spacing:-1px;word-spacing:-1.3px;}
#t15_150{left:43px;top:520px;letter-spacing:-1px;word-spacing:4.7px;}
#t16_150{left:43px;top:535px;letter-spacing:-0.9px;word-spacing:-0.1px;}
#t17_150{left:43px;top:570px;letter-spacing:-1px;word-spacing:-0.1px;}

.s1_150{
	FONT-SIZE: 48.9px;
	FONT-FAMILY: AllerDisplay_lq;
	color: rgb(156,100,158);
}

.s2_150{
	FONT-SIZE: 48.9px;
	FONT-FAMILY: AllerDisplay_lq;
	color: rgb(35,31,32);
}

.s3_150{
	FONT-SIZE: 39.7px;
	FONT-FAMILY: AllerDisplay_lq;
	color: rgb(255,255,255);
}

.s4_150{
	FONT-SIZE: 48.9px;
	FONT-FAMILY: Helvetica-Condensed_ix;
	color: rgb(35,31,32);
}

.s5_150{
	FONT-SIZE: 48.9px;
	FONT-FAMILY: Helvetica-Condensed-Bold_j0;
	color: rgb(35,31,32);
}

.s6_150{
	FONT-SIZE: 48.9px;
	FONT-FAMILY: HelveticaNeue-LightCondOb_j8;
	color: rgb(35,31,32);
}

.s7_150{
	FONT-SIZE: 48.9px;
	FONT-FAMILY: Symbol_j9;
	color: rgb(35,31,32);
}

.t.m0_150{
	-webkit-transform: matrix(0,-1,1,0,0, 0) scale(0.25);
	-ms-transform: matrix(0,-1,1,0,0, 0) scale(0.25);
	-moz-transform: matrix(0,-1,1,0,0, 0) scale(0.25);
	-o-transform: matrix(0,-1,1,0,0, 0) scale(0.25);
}

</style>
<!-- End inline CSS -->

<!-- Begin embedded font definitions -->
<style id="fonts150" type="text/css" >

@font-face {
	font-family: HelveticaNeue-LightCondOb_j8;
	src: url("fonts/HelveticaNeue-LightCondOb_j8.woff") format("woff");
}

@font-face {
	font-family: Symbol_j9;
	src: url("fonts/Symbol_j9.woff") format("woff");
}

@font-face {
	font-family: Helvetica-Condensed-Bold_j0;
	src: url("fonts/Helvetica-Condensed-Bold_j0.woff") format("woff");
}

@font-face {
	font-family: AllerDisplay_lq;
	src: url("fonts/AllerDisplay_lq.woff") format("woff");
}

@font-face {
	font-family: Helvetica-Condensed_ix;
	src: url("fonts/Helvetica-Condensed_ix.woff") format("woff");
}

</style>
<!-- End embedded font definitions -->

<!-- Begin page background -->
<div id="pg150Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg150" style="-webkit-user-select: none;"><object width="433" height="649" data="150/150.svg" type="image/svg+xml" id="pdf150" style="width:433px; height:649px; -moz-transform:scale(1); z-index: 0;"></object></div>
<!-- End page background -->


<!-- Begin text definitions (Positioned/styled in CSS) -->
<div id="t1_150" class="t m0_150 s1_150">O Guia do Jovem Internista </div>
<div id="t2_150" class="t m0_150 s2_150">2016</div>
<div id="t3_150" class="t s3_150">148</div>
<div id="t4_150" class="t s4_150">casos que não apresentaram melhora clínica ou em imagem de </div>
<div id="t5_150" class="t s4_150">controle).</div>
<div id="t6_150" class="t s4_150">-</div>
<div id="t7_150" class="t s5_150">LAB:</div>
<div id="t8_150" class="t s4_150">A serologia para toxoplasmose (IgG) é positiva na grande </div>
<div id="t9_150" class="t s4_150">maioria dos doentes com neurotoxoplasmose, pelo que geralmente </div>
<div id="ta_150" class="t s4_150">tem pouca utilidade no diagnóstico. A identificação de IgG negativa </div>
<div id="tb_150" class="t s4_150">para toxoplasmose torna o diagnóstico menos provável, mas não </div>
<div id="tc_150" class="t s4_150">o exclui.</div>
<div id="td_150" class="t s4_150">PCR positivo no LCR para </div>
<div id="te_150" class="t s6_150">Toxoplasma gondii</div>
<div id="tf_150" class="t s4_150">apresenta elevada espe-</div>
<div id="tg_150" class="t s4_150">cificidade (superior a 95%), porém com baixa sensibilidade (50%)</div>
<div id="th_150" class="t s4_150">Cultura só nos laboratórios especializados.</div>
<div id="ti_150" class="t s5_150">• Tratamento</div>
<div id="tj_150" class="t s4_150">- Pirimetamina 200 mg PO - dose carga </div>
<div id="tk_150" class="t s4_150">- </div>
<div id="tl_150" class="t s4_150">Peso corporal </div>
<div id="tm_150" class="t s7_150">²</div>
<div id="tn_150" class="t s4_150">60 kg: Pirimetamina 50mg dia PO + Sulfadiazina </div>
<div id="to_150" class="t s4_150">1000mg PO 6/6h+ Ac. Fólico 10-25mg dia PO dia</div>
<div id="tp_150" class="t s4_150">- </div>
<div id="tq_150" class="t s4_150">Peso corporal &gt;60 kg: Pirimetamina 75mg dia PO + Sulfadiazina </div>
<div id="tr_150" class="t s4_150">1500mg PO 6/6h +Ac.fólico 10-25mg dia PO dia</div>
<div id="ts_150" class="t s4_150">Duração do tratamento:</div>
<div id="tt_150" class="t s4_150">- </div>
<div id="tu_150" class="t s4_150">Mínimo 6 semanas (pode ser mais se doença extensa ou resposta </div>
<div id="tv_150" class="t s4_150">incompleta depois de 6 semanas)</div>
<div id="tw_150" class="t s4_150">Alternativas: </div>
<div id="tx_150" class="t s4_150">- Pirimetamina + Clindamicina 600mg IV </div>
<div id="ty_150" class="t s4_150">- SMX + TMP (SMX 25mg/kg </div>
<div id="tz_150" class="t s4_150">+ TMP 5mg/kg) 2xdia</div>
<div id="t10_150" class="t s4_150">- Atovaquona 1500mg PO 2xdia + Pirimetamina</div>
<div id="t11_150" class="t s4_150">- Atovaquona 1500mg PO 2xdia + Sulfadiazina</div>
<div id="t12_150" class="t s4_150">- Atovaquona 1500mg PO 2xdia</div>
<div id="t13_150" class="t s4_150">- Pirimetamina + Azitromicina 900-1200mg 1xdia</div>
<div id="t14_150" class="t s4_150">Indica-se o uso de corticosteróides nos casos de edema cerebral difuso </div>
<div id="t15_150" class="t s4_150">e/ou intenso efeito de massa (desvio de linha média, compressão de </div>
<div id="t16_150" class="t s4_150">estruturas adjacentes). </div>
<div id="t17_150" class="t s4_150">Não se indica o uso profilático de anticonvulsivantes</div>

<!-- End text definitions -->


</div>
</body>
</html>
